Navigation Links
Prostate screening studies reviewed in European Urology July issue
Date:6/29/2009

Arnhem, June 2009 The July issue of European Urology, the official journal of the European Association of Urology, features an editorial by Lars Holmberg comparing the results from the European Randomised Study of Screening for Prostate Cancer (ERSPC) with the results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) In the editorial, Professor Holmberg writes that "The studies illustrate that the price to pay for 20% reduction in prostate cancer deaths is high; overdiagnosis and overtreatment are great problems. The answers lie in improving the PSA test or finding biomarkers that effectively separate aggressive cancers from slow-growing ones. We identify some priorities in the discussion about PSA testing."

Another article of interest in this issue is "Testosterone and Prostate Cancer: Revisiting Old Paradigms" by H. Isbarn et al. The notion that pathologic prostate growth, benign or malignant, can be stimulated by androgens is a commonly held beliefbut one without scientific basis. In the article, Dr. Isbarn writes that, "We therefore conducted a Medline search to identify articles addressing the relationship between testosterone and the risk of prostate cancer development. Although large prospective studies addressing the long-term effect of testosterone treatment are needed to either refute or corroborate the hypothesis, the available literature strongly suggests that testosterone treatment neither increases the risk of prostate cancer diagnosis in normal men nor causes cancer recurrence in men who were successfully treated for prostate cancer."

Next month, European Urology will publish the EAU position statement on screening for prostate cancer which takes into consideration the recent scientific information on randomised screening studies on prostate cancer (Schrder et al, NEJM 2009). The EAU adopts the conclusions of the ERSPC study and recognises the benefit of screening in terms of mortality reduction, as well as the adverse effects of overdiagnosis and overtreatment of prostate cancers which could be quantified for the first time in the setting of a randomised screening study.


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. First biomarker discovered that predicts prostate cancer outcome
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Red wine compound shown to prevent prostate cancer
7. Barbershop Talks Cut Black Mens Prostate Cancer Risk
8. Generic prostate drug helps find high-risk cancers early
9. Finasteride unlikely to induce high grade prostate cancers
10. Shrinkage of prostate led to overestimation of cancer risk in trial
11. Prostate Cancer Awareness Week to Screen Thousands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional ... it has enlisted New York City-based sports and entertainment marketing firm Leverage Agency ... sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ever title ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy ... "Wonder Spice", it has been used for thousands of years. , "The West has ... author of " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... provides insight into the challenges employers face in trying to balance both short-term ... employee benefits programs? Adding to the growing complexity, companies are finding that ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... documenting and diagramming network and data center assets and audio-video devices has recently ... request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Calif. , March 29, 2017  Designers of ... significantly reduce solution size by 50% and extend battery ... ) power management integrated circuit (PMIC) from Maxim Integrated ... PMIC supports a low input voltage of just 0.7V ... Air and Silver Oxide, as well as the more ...
(Date:3/29/2017)... , March 29, 2017  NuVasive, Inc. (NASDAQ: ... transforming spine surgery with minimally disruptive, procedurally-integrated solutions, ... 510(k) clearance of the CoRoent® Small Interbody™ System ... levels in the cervical spine. This marks the ... be used at up to four contiguous levels. ...
(Date:3/29/2017)... HEIGHTS, Utah , March 29, 2017 /PRNewswire/ ... ) announced today the appointment of Cynthia ... Operations.  Cyndi will be responsible for leading Dynatronics ... organization and will report to Dynatronics, CEO ... Cyndi,s appointment concludes an extensive search process conducted ...
Breaking Medicine Technology: